Pila Pharma AB

About:

Pila Pharma AB is a TRPV1-platform focused company developing oral treatments for Type-2 Diabetes, Obesity & Pain

Website: http://pilapharma.com/

Twitter/X: PilaPharma

Top Investors: Almi Invest, EASME - EU Executive Agency for SMEs, Dorte Xenia Gram

Description:

Pila Pharma AB is a clinical stage biotech company developing a potent, selective TRPV1 antagonist, XEN-D0501, as treatment of type 2 diabetes, obesity and the rare painful disease erythromelalgia. XEN-D0501 has been tested in 300 subjects in phase 1 and 2 and has a demonstrated good safety profile in healthy volunteers and in patients with overactive bladder disease, chronic cough or type 2 diabetes as well as efficacy in type 2 diabetics on improving glucose stimulated insulin secretion. Recently, 13 week preclinical safety studies with XEN-D0501 completed without registration of side effects and the molecule can therefore progress to clinical trials of up to 3 months duration. In July 2022, the company received US Orphan Drug Designation for XEN-D0501 as treatment as the rare and painful disease erythromelalgia. The company is based in Malmö, Sweden and is listed on Nasdaq First North GM, Stockholm, since July 2021.